恩格列淨
參考資料

↑  Elizabeth Mechatie for Clinical Endocrinology News Digital Network August 1, 2014 FDA approves empagliflozin for adults with type 2 diabetes
↑  . www.boehringer-ingelheim.cn.   [2021-03-26]. （原始内容存档于2020-12-03）.
↑  Goldenberg R, et al. Can J Diabetes. 2016;40:193-195.
1 2  Abdul-Ghani et al. SGLT2 inhibition and Type 2 Diabetes. Endocrine Reviews, August 2011, 32(4):515–531
↑  Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin.2009; 25(3):671-81.
↑  Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications; Diabetic Med. 2010;27:136–142
↑  Rahmouneet.al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non–insulin-dependent diabetes; Diabetes, Vol. 54, December 2005: 3427-34
↑  Rosenstock J, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with Type 2 Diabetes. Diabetes Care. 2012.
↑  List JF, et al. Sodium-glucose cotransport inhibition with dapagliflozin in Type 2     Diabetes. Diabetes Care 2009; 32:650-7.
↑  Wilding JPH, et al. A study of dapagliflozin in patients with Type 2 Diabetes  receiving high doses of insulin plus insulinsensitizers.Diabetes Care.2009; 32:1656-62.
↑  Zhang L, et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes, Obesity and Metabolism.2010; 12:510-6.
1 2  Zinman, B., et al. “Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes” N Engl J Med. 10.1056 (2015).
↑   Zinman B, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol. 2014;13:102.
↑  The Emerging Risk Factors Collaboration: Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015;314(1):52-60.
↑  Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. The British Journal of Diabetes & Vascular Disease. 2013;13(4):192-207.
↑   Morrish NJ, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001; 44 Suppl 2:S14-21.
↑   Zinman, B., et al. “Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes” N Engl J Med. 10.1056 (2015).
↑  Wanner C, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016.
↑   Thomas MC. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. National Review of Nephrology. 2016;12(2):73-81.
↑  National Kidney Foundation. Diabetes and kidney failure (stage 5). Available from: www.kidney.org/atoz/content/Diabetes-and-Kidney-Failure-Stage5 (Last accessed: May 2016).
↑  Gansevoort RT, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. The Lancet. 2013;382:339-52
↑  New England Journal of Medicine 2015. http://www.nejm.org/doi/full/10.1056/NEJMoa1504720#t=article （页面存档备份，存于）. Last accessed: Jan 2016.
↑  New England Journal of Medicine 2016. http://www.nejm.org/doi/full/10.1056/NEJMoa1515920#t=article （页面存档备份，存于）. Last accessed: Jun 2016.
↑  ClinicalTrials.gov. Phase III trials of empagliflozin/BI10773. Available at: http://clinicaltrials.gov （页面存档备份，存于）. Last accessed: August2012.
↑  Rosenstock, J. et al. Efficacy and safety of bi 10773, a new sodium glucose cotransporter-2 (sglt-2) inhibitor, in Type 2Diabetes inadequately controlled on metformin. Presented at 71st Scientific Sessions of the American Diabetes Association, 2011. Poster No. 989
↑  Woerle, H. J. et al. Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-labelextension study in patients with type 2 diabetes. Presented at 72nd Scientific Sessions of the American Diabetes Association, 2012.Poster No. 49-LB.
↑  Heise, T. et al. BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), is safe and efficacious following 4-weektreatment in patients with type 2 diabetes, Presented at 70th Scientific Sessions of the American Diabetes Association,2010. Poster No. 629-P
↑   Ferrannini, E. et al. The potent and highly selective sodium-glucose co-cransporter (SGLT-2) inhibitor BI 10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus, European Association for the Study of Diabetes, 2010.Abstract 877
↑  Zinman. B. et al. Design of the empagliflozin cardiovascular (CV) outcome event trial in Type 2 Diabetes (T2D). Presentedat 73rd Scientific Sessions of the American Diabetes Association, 2013. Poster No. 2349-P